miR-101-3p的生物学功能及其在心血管疾病中的研究进展

doi:10.11958/20252447

天津医药 ›› 2025, Vol. 53 ›› Issue (11): 1223-1228.doi: 10.11958/20252447

miR-101-3p的生物学功能及其在心血管疾病中的研究进展

庞志华¹(), 刘丽美², 姚朱华^1△()

¹ 天津市人民医院（南开大学第一附属医院）心内科（邮编 300121）
² 天津市滨海新区大港医院重症医学科

收稿日期:2025-07-09 修回日期:2025-08-08 出版日期:2025-11-15 发布日期:2025-11-19
通讯作者: △E-mail：yaozhuhua021@126.com
作者简介:庞志华（1979），男，副主任医师，主要从事冠心病、心力衰竭方面研究。E-mail：hz1126@126.com
基金资助:
天津市科技计划项目(22JCYBJC00580)

Research progress of biological functions of miR-101-3p in cardiovascular diseases

PANG Zhihua¹(), LIU Limei², YAO Zhuhua^1△()

¹ Department of Cardiology, Tianjin Union Medical Center, the First Affiliated Hospital of Nankai University, Tianjin 300121, China
² Intensive Care Unit, Tianjin Binhai New Area Dagang Hospital

Received:2025-07-09 Revised:2025-08-08 Published:2025-11-15 Online:2025-11-19
Contact: △E-mail：yaozhuhua021@126.com

庞志华, 刘丽美, 姚朱华. miR-101-3p的生物学功能及其在心血管疾病中的研究进展[J]. 天津医药, 2025, 53(11): 1223-1228.

PANG Zhihua, LIU Limei, YAO Zhuhua. Research progress of biological functions of miR-101-3p in cardiovascular diseases[J]. Tianjin Medical Journal, 2025, 53(11): 1223-1228.

摘要/Abstract

摘要：

miR-101-3p是进化保守的非编码RNA，近年来在多种心血管疾病（CVD）中显示异常表达和关键调控功能。其可通过调节凋亡、自噬与代谢等通路，广泛参与心肌梗死后心肌重构过程、心力衰竭中纤维化进展和动脉粥样硬化的形成机制，并在系统性疾病相关心肌损伤中具备免疫调节潜力。该文综述了miR-101-3p在CVD中的研究进展，系统探讨其在不同疾病模型中的表达模式与调控机制，阐述其在心血管疾病发生发展中的生物学效应，并展望其作为潜在诊断标志物与治疗靶点的临床应用前景。miR-101-3p有望为心血管疾病的早期筛查和精准治疗提供新的生物学依据与干预思路。

关键词: 心肌梗死, 心力衰竭, 动脉粥样硬化, miR-101-3p, 心肌纤维化

Abstract:

miR-101-3p is an evolutionarily conserved non-coding RNA that has shown aberrant expression and regulatory functios in various cardiovascular diseases (CVDs) in recent years. It participates in key pathological processes including post-infarction myocardial remodeling, myocardial fibrosis in heart failure and the development of atherosclerosis by modulating pathways such as apoptosis, autophagy and metabolism. In addition, it exhibits immunoregulatory potential in myocardium injury related to systemic diseases. This review summarizes the recent advances in understanding the role of miR-101-3p in CVDs, focusing on its expression dynamics and regulatory mechanisms in different disease models. It further elaborates on the biological effects of miR-101-3p in cardiovascular pathology and explores its potential as a diagnostic biomarker and therapeutic target. miR-101-3p is expected to provide novel insights for early detection and targeted intervention of cardiovascular diseases.

Key words: myocardial infarction, heart failure, atherosclerosis, miR-101-3p, myocardial fibrosis

中图分类号:

R541.4

参考文献 42

[1]	CHONG B, JAYABASKARAN J, JAUHARI S M, et al. Global burden of cardiovascular diseases:projections from 2025 to 2050[J]. Eur J Prev Cardiol, 2025, 32(11):1001-1015. doi:10.1093/eurjpc/zwae281.
[2]	CIPRIANO G L, SCHEPICI G, MAZZON E, et al. Multiple sclerosis:Roles of miRNA,lcnRNA,and circRNA and their implications in cellular pathways[J]. Int J Mol Sci, 2024, 25(4):2255. doi:10.3390/ijms25042255.
[3]	吴宾, 杨自更, 金玲, 等. miRNA-381-3p/MuRF1轴对低氧性肺动脉高压小鼠心肺损伤的影响[J]. 天津医药, 2025, 53(6):571-577.
	WU B, YANG Z G, JIN L, et al. Effect of miRNA-381-3p/MuRF1 axis on cardiopulmonary injury in mice with hypoxic pulmonary hypertension[J]. Tianjin Med J, 2025, 53(6):571-577. doi:10.11958/20251127.
[4]	PONTEMEZZO E, FOGLIO E, VERNUCCI E, et al. miR-200c-3p regulates epitelial-to-mesenchymal transition in epicardial mesothelial cells by targeting epicardial follistatin-related protein 1[J]. Int J Mol Sci, 2021, 22(9):4971. doi:10.3390/ijms22094971.
[5]	DUEÑAS A, EXPÓSITO A, MUÑOZ M, et al. MiR-195 enhances cardiomyogenic differentiation of the proepicardium/septum transversum by Smurf1 and Foxp1 modulation[J]. Sci Rep, 2020, 10(1):9334. doi:10.1038/s41598-020-66325-x.
[6]	KHIDR E G, ABULSOUD A I, DOGHISH A A, et al. The potential role of miRNAs in the pathogenesis of cardiovascular diseases - A focus on signaling pathways interplay[J]. Pathol Res Pract, 2023, 248:154624. doi:10.1016/j.prp.2023.154624.
[7]	XIN Y, TANG L, CHEN J, et al. Inhibition of miR-101-3p protects against sepsis-induced myocardial injury by inhibiting MAPK and NF-κB pathway activation via the upregulation of DUSP1[J]. Int J Mol Med, 2021, 47(3):20. doi:10.3892/ijmm.2021.4853.
[8]	GRIFFITHS-JONES S, GROCOCK R J, VAN DONGEN S, et al. miRBase:microRNA sequences,targets and gene nomenclature[J]. Nucleic Acids Res, 2006, 34(Database issue):D140-144. doi:10.1093/nar/gkj112.
[9]	LIU N, YANG C, GAO A, et al. MiR-101: An important regulator of gene expression and tumor ecosystem[J]. Cancers(Basel), 2022, 14(23):5861. doi:10.3390/cancers14235861.
[10]	GUO X, CHEN M, CAO L, et al. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via miR-101-3p mediated VEGFA secretion and AKT/eNOS pathway[J]. Frontiers in cell and developmental biology, 2021, 9:764151. doi:10.3389/fcell.2021.764151.
[11]	WANG J, ZHANG W, ZHANG R, et al. MiR-101-3p promotes tumor cell proliferation and migration via the wnt signal pathway in MNNG-induced esophageal squamous cell carcinoma[J]. Toxics, 2024, 12(11):824. doi:10.3390/toxics12110824.
[12]	LIU M, GAO H, HE Y, et al. Upregulation of miR-101-3p overcomes ibrutinib resistance by targeting ABCC5 in diffuse large B-cell lymphoma(DLBCL)[J]. Journal of Hard Tissue Biology, 2023, 32(1):11-20. doi:10.2485/jhtb.32.11.
[13]	WANG H, WANG L, ZHANG G, et al. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer[J]. Oncotarget, 2018, 9(7):7501-7512. doi:10.18632/oncotarget.23483.
[14]	BAKHSHI A, KHANI M, ALIPOUR PARSA S, et al. Investigating the expression level of miR-17-3p,miR-101-3p,miR-335-3p,and miR-296-3p in the peripheral blood of patients with acute myocardial infarction[J]. Mol Cell Biochem, 2024, 479(4):859-868. doi:10.1007/s11010-023-04766-4.
[15]	WANG J, YANG X, LI R, et al. LncRNA SNHG6 inhibits apoptosis by regulating EZH2 expression via the sponging of miR-101-3p in esophageal squamous-cell carcinoma[J]. Onco Targets Ther, 2020, 13:11411-11420. doi:10.2147/OTT.S275135.
[16]	ABDI J, RASTGOO N, CHEN Y, et al. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells[J]. BMC Cancer, 2019, 19(1):975. doi:10.1186/s12885-019-6151-x.
[17]	ZHU W, NI Q, WANG Z, et al. MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion,proliferation,and epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Clin Exp Med, 2025, 25(1):88. doi:10.1007/s10238-025-01622-1.
[18]	SUN H, ZHU R, GUO X, et al. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2[J]. Pathol Res Pract, 2024, 256:155271. doi:10.1016/j.prp.2024.155271.
[19]	PARK J, CHO M, CHO J, et al. MicroRNA-101-3p suppresses cancer cell growth by inhibiting the USP47-induced deubiquitination of RPL11[J]. Cancers(Basel), 2022, 14(4):964. doi:10.3390/cancers14040964.
[20]	TAO L, XU C, SHEN W, et al. HIPK3 inhibition by exosomal hsa-miR-101-3p is related to metabolic reprogramming in colorectal cancer[J]. Front Oncol, 2021, 11:758336. doi:10.3389/fonc.2021.758336.
[21]	ZIEMANN M, LIM S C, KANG Y, et al. MicroRNA-101-3p modulates mitochondrial metabolism via the regulation of complex II assembly[J]. J Mol Biol, 2022, 434(2):167361. doi:10.1016/j.jmb.2021.167361.
[22]	HUA G, ZENG Z L, SHI Y T, et al. LncRNA XIST contributes to cisplatin resistance of lung cancer cells by promoting cellular glycolysis through sponging miR-101-3p[J]. Pharmacology, 2021, 106(9/10):498-508. doi:10.1159/000512621.
[23]	XU C F, CAO Q, ZHANG B F. Catalpol improves insulin resistance and lipid metabolism disorder in diabetic mice by inhibiting microRNA-101-3p to up-regulate FOS-related antigen 2[J]. J Physiol Pharmacol, 2024, 75(3). doi:10.26402/jpp.2024.3.05. [Epub 2024 Jul 18]
[24]	MAHMOUDIAN ESFAHANI M, MOSTASHFI M, VAHEB HOSSEINABADI S, et al. Unveiling the regulatory of miR-101-3p on ZNF746 in a Parkinson's disease cell model:Implications for therapeutic targeting[J]. Neurosci Res, 2024, 203:18-27. doi:10.1016/j.neures.2023.12.001.
[25]	ZHANG T, ZHAO S, GU C. Role of PGC-1α in the proliferation and metastasis of malignant tumors[J]. J Mol Histol, 2025, 56(2):77. doi:10.1007/s10735-025-10360-3.
[26]	ZHANG Y, WANG Y, ZHAO F. Application of the trend of miRNA expression levels in APP/PS1 mice plasma for the early diagnosis of Alzheimer's disease[J]. Mol Neurobiol, 2025, 62(6):7792-7804. doi:10.1007/s12035-025-04743-6.
[27]	SONG L, FENG S, YU H, et al. Dexmedetomidine protects against kidney fibrosis in diabetic mice by targeting miR-101-3p-mediated EndMT[J]. Dose Response, 2022, 20(1):15593258221083486. doi:10.1177/15593258221083486.
[28]	ZHANG J, XU X, WANG M. Clinical significance of serum miR-101-3p expression in patients with neonatal sepsis[J]. Per Med, 2021, 18(6):541-550. doi:10.2217/pme-2020-0182.
[29]	ZHAO X, LI S, WANG Z, et al. miR-101-3p negatively regulates inflammation in systemic lupus erythematosus via MAPK1 targeting and inhibition of the NF-κB pathway[J]. Mol Med Rep, 2021, 23(5):359. doi:10.3892/mmr.2021.11998.
[30]	CHEN Q, LI X, KONG L, et al. miR-101-3p induces vascular endothelial cell dysfunction by targeting tet methylcytosine dioxygenase 2[J]. Acta Biochim Biophys Sin(Shanghai), 2020, 52(2):180-191. doi:10.1093/abbs/gmz154.
[31]	谢田田, 赵春虎, 袁文生, 等. 老年急性ST段抬高型心肌梗死患者血清lnc-MALAT1、miR-101-3p水平与心功能分级及短期预后的相关性[J]. 中国老年学杂志, 2024, 44(16):3841-3844.
	XIE T T, ZHAO C H, YUAN W S, et al. Correlation between serum lnc-MALAT1 and miR-101-3p levels and cardiac function classification and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction[J]. Chinese Journal of Gerontology, 2024, 44(16):3841-3844. doi:10.3969/j.issn.1005-9202.2024.16.001.
[32]	SANTOS-FARIA J, GAVINA C, RODRIGUES P, et al. MicroRNAs and ventricular remodeling in aortic stenosis[J]. Rev Port Cardiol(Engl Ed), 2020, 39(7):377-387. doi:10.1016/j.repc.2019.09.014.
[33]	CHEN J, LIN Y, SUN Z. Inhibition of miR-101-3p prevents human aortic valve interstitial cell calcification through regulation of CDH11/SOX9 expression[J]. Mol Med, 2023, 29(1):24. doi:10.1186/s10020-023-00619-4.
[34]	WAN F, MA X, WANG J, et al. Evaluation of left ventricular dysfunction by three-dimensional speckle-tracking echocardiography and bioinformatics analysis of circulating exosomal miRNA in obese patients[J]. BMC Cardiovasc Disord, 2023, 23(1):450. doi:10.1186/s12872-023-03502-6.
[35]	PAN Z, SUN X, SHAN H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway[J]. Circulation, 2012, 126(7):840-850. doi:10.1161/CIRCULATIONAHA.112.094524.
[36]	CHENG S, ZHOU F, XU Y, et al. Geniposide regulates the miR-101/MKP-1/p38 pathway and alleviates atherosclerosis inflammatory injury in ApoE-/- mice[J]. Immunobiology, 2019, 224(2):296-306. doi:10.1016/j.imbio.2018.12.005.
[37]	TAN W H, PENG Z L, YOU T, et al. CTRP15 promotes macrophage cholesterol efflux and attenuates atherosclerosis by increasing the expression of ABCA1[J]. J Physiol Biochem, 2022, 78(3):653-666. doi:10.1007/s13105-022-00885-6.
[38]	JIANG H, TOSCANO J F, SONG S S, et al. Differential expression of circulating exosomal microRNAs in refractory intracranial atherosclerosis associated with antiangiogenesis[J]. Sci Rep, 2019, 9(1):19429. doi:10.1038/s41598-019-54542-y.
[39]	LI Y, DU L, MENG L, et al. High expression of CASP1 induces atherosclerosis[J]. Medicine(Baltimore), 2024, 103(16):e37616. doi:10.1097/MD.0000000000037616.
[40]	MAYR B, MÜLLER E E, SCHÄFER C, et al. Exercise-induced changes in miRNA expression in coronary artery disease[J]. Clin Chem Lab Med, 2021, 59(10):1719-1727. doi:10.1515/cclm-2021-0164.
[41]	SANTOS A S, CUNHA NETO E, FUKUI R T, et al. Increased expression of circulating microRNA 101-3p in type 1 diabetes patients:New insights into miRNA-regulated pathophysiological pathways for type 1 diabetes[J]. Front Immunol, 2019, 10:1637. doi:10.3389/fimmu.2019.01637.
[42]	蒋凯, 陈永顺. miR-101-3p通过MAPK信号通路保护心肌缺血再灌注损伤的机制研究[J]. 现代医学, 2022, 50(6):665-671.
	JIANG K, CHEN Y S. Mechanism of miR-101-3p protecting myocardial ischemia-reperfusion injury through MAPK signaling pathway[J]. Modern Medical Journal, 2022, 50(6):665-671. doi:10.3969/j.issn.1671-7562.2022.06.001.

miR-101-3p的生物学功能及其在心血管疾病中的研究进展

Research progress of biological functions of miR-101-3p in cardiovascular diseases

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李迎杰, 张航, 郝少婷, 许菲, 郭魏超, 宋惠, 王艳芬. 生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭的疗效观察[J]. 天津医药, 2025, 53(8): 860-864.
[2]	陈英, 郭长英, 张静, 李娟, 陈丰毅. 基于术前肺动脉压评估心脏移植术后右心衰竭的发生风险[J]. 天津医药, 2025, 53(7): 751-755.
[3]	吴宾, 杨自更, 金玲, 张婧, 韦红梅, 蔡冰冰, 魏玉英. miRNA-381-3p/MuRF1轴对低氧性肺动脉高压小鼠心肺损伤的影响[J]. 天津医药, 2025, 53(6): 571-577.
[4]	陈珍进, 金晓青, 祁安宁, 韩崇旭. 血浆血管性血友病因子抗原水平对老年急性心肌梗死患者长期预后的预测价值[J]. 天津医药, 2025, 53(6): 589-593.
[5]	董玉婷, 龚雪莲, 屈超. 慢性心力衰竭患者血浆IGFBP2、SMOC2水平与心功能及预后的关系[J]. 天津医药, 2025, 53(6): 593-598.
[6]	邓子昊, 黄欣扬, 钟坤江, 赵博. 纳米材料在动脉粥样硬化性心血管疾病中的应用进展[J]. 天津医药, 2025, 53(5): 556-560.
[7]	胡紫月, 郑茹瑜, 刘丹, 唐姗, 阚艳敏, 经翔, 李倩. 颈动脉粥样硬化斑块近心端角度与新生血管评分对脑梗死的预测价值[J]. 天津医药, 2025, 53(4): 439-443.
[8]	吴宾, 杨自更, 张婧, 李书红, 余凤, 王嘉玮, 李彩玲. 柚皮素对低氧性肺动脉高压大鼠右心室重塑的影响[J]. 天津医药, 2025, 53(2): 129-134.
[9]	吕婧, 朱方颖, 朱凯, 李云, 杨娜, 温淑云, 仲米倩. 类风湿关节炎患者动脉粥样硬化风险预测模型的构建与验证[J]. 天津医药, 2025, 53(10): 1043-1047.
[10]	金佳纯, 陆彩霞, 吴燕君. 中性粒细胞胞外诱捕网对动脉粥样硬化性心血管病的作用机制及其研究进展[J]. 天津医药, 2025, 53(10): 1104-1109.
[11]	赵树站, 金冬霞, 李曦铭, 郝天旭, 陆艺蓓. 低密度脂蛋白跨内皮细胞转运机制的研究进展[J]. 天津医药, 2025, 53(10): 1110-1115.
[12]	刘欢, 张琦, 闫启鹍, 曹路. 首次医疗接触QRS时限与急性ST段抬高型心肌梗死临床终点关系的单中心研究[J]. 天津医药, 2025, 53(1): 71-74.
[13]	张婕, 刘向龙, 张静. 左西孟旦联合依那普利治疗急性前壁心肌梗死急诊PCI术后合并心功能不全的临床研究[J]. 天津医药, 2025, 53(1): 98-102.
[14]	杨睿, 魏琼, 孙逸坤, 赵梦竹, 程序, 刘梦华, 张冬梅. 缺氧H9c2来源外泌体对HUVEC增殖、迁移和成管能力的影响[J]. 天津医药, 2024, 52(7): 714-719.
[15]	徐斌, 诸赟, 陈浩, 朱红俊, 高枫, 夏丛奕, 钟玲, 苏伟. 超滤治疗老年心力衰竭合并衰弱患者的有效性及安全性[J]. 天津医药, 2024, 52(7): 743-747.